NCT00314093View on ClinicalTrials.gov

RFT-5-dgA in Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Metastatic Melanoma
Interventions
DRUG

RFT5pdgA

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT00314093 - RFT-5-dgA in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter